iRhythm Holdings, Inc. Common Stock (IRTC) Stock Price
IRTCStock
$108.66−39.97%52W
Market Cap$3.58B
P/E—
PEG Ratio—
Div yield—
Beta1.50
IRTC Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-21.73%
Price vs S&P 500 (4W)-0.23%
VGM Score51.26
IRTC Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.04 | $0.58 | +1258.00%(+$0.54) | |
| Q1 2026 | -$0.64 | -$0.35 | +45.29%(+$0.29) | |
| Q4 2025 | $0.06 | $0.29 | +410.56%(+$0.23) | |
| Q3 2025 | -$0.28 | -$0.06 | +78.75%(+$0.22) | |
| Q2 2025 | -$0.47 | -$0.32 | +32.55%(+$0.15) |
IRTC Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.33
4.33
4.43
4.43
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
IRTCiRhythm Holdings, Inc. Common Stock | D | B | C | 4.3x | 23.0% | 71.5% | -3.0% | $108.66 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About iRhythm Holdings, Inc. Common Stock
iRhythm Holdings develops and commercializes the Zio System, an FDA-cleared digital platform for ambulatory cardiac monitoring that combines a wire-free, wearable biosensor with proprietary cloud-based analytics software. The system enables clinicians to diagnose arrhythmias more quickly and efficiently than traditional monitoring methods by continuously recording electrocardiogram data over 14 days. Designed for improved diagnostic accuracy and clinical efficiency, Zio addresses a key need in cardiac care monitoring.